Ozempic, a prescription medication developed by Novo Nordisk, is primarily utilized to control high blood sugar in individuals with type 2 diabetes.
Its active ingredient, semaglutide, functions as a GLP-1 receptor agonist—a type of drug that mimics an incretin hormone to stimulate insulin production in the pancreas.
This effect not only aids in lowering blood glucose levels but also slows gastric emptying and can contribute to weight loss.
With obesity being a common comorbidity of diabetes, the dual action of Ozempic has positioned it as both a diabetes therapy and a weight management tool.
Despite its therapeutic benefits, scrutiny around Ozempic has intensified due to serious side effects reported by some patients; notable among these is stomach paralysis or severe gastroparesis—an adverse event where the stomach takes longer than normal to empty its contents.
This condition can lead to debilitating symptoms such as nausea and vomiting, ultimately impacting quality of life.
As reports emerge connecting Ozempic usage with this severe gastrointestinal issue, affected patients are seeking compensation through legal channels for what they allege was inadequate warning of potential risks associated with taking this diabetes drug.